98857-08-0Relevant articles and documents
Enzymatic synthesis of optically active 1- and 2-aminoalkanephosphonates
Yuan, Chengye,Xu, Chengfu,Zhang, Yonghui
, p. 6095 - 6102 (2003)
A number of 1- and 2-aminoalkanephosphonates were resolved with high enantioselectivity by Candida antarctica lipase B-catalyzed acetylation. By this method, optically pure aminoalkanephosphonates and amidoalkanephosphonates, the precursors of the corresponding aminoalkanephosphonic acids, were synthesized.
THERAPEUTICALLY USEFUL ANTIBACTERIAL COMPOUNDS
-
Page/Page column 16, (2010/02/13)
Disclosed is a compound which has antibiotic activity in vivo in a mammalian, preferably a human, subject, the compound comprising an uptake moiety linked to a bactericidal or bacteriostatic toxic moiety, said uptake moiety facilitating uptake of the comp
Optically active diethyl N-(p-toluenesulfonyl)-aziridine 2-phosphonates as chiral synthons for the synthesis of β-substituted α-amino phosphonates
Dolence, E. Kurt,Roylance, Jason B.
, p. 3307 - 3322 (2007/10/03)
A versatile approach for the synthesis of both protected enantiomers of aziridine 2-phosphonates for use as chiral synthons has been developed. The aziridines arise from either (R)- or (S)-phosphonoserine diethyl esters followed by N-tosylation, O-mesylat
Synthesis and structure-activity relationships of antibacterial phosphonopeptides incorporating (1-aminoethyl)phosphonic acid and (aminomethyl)phosphonic acid
Atherton,Hassall,Lambert
, p. 29 - 40 (2007/10/02)
Phosphonodipeptides and phosphonooligopeptides based on L- and D-(1-aminoethyl)phosphonic acids L-Ala(P) and D-Ala(P) and (aminomethyl)phosphonic acid Gly(P) at the acid terminus have been synthesized and investigated as antibacterial agents, which owe their activity to the inhibition of bacterial cell-wall biosynthesis. A method for large-scale synthesis of the potent antibacterial agent L-Ala-L-Ala(P) (1,Alafosfalin) is described. Structure-activity relationships in the dipeptide series have been studied by systematic variation of structure 1. L stereochemistry is generally required for both components. Changes in the L-Ala(P) moiety mostly lead to loss of antibacterial activity, but the phosphonate analogues of L-phenylalanines, L-Phe(P), and L-serine, L-Ser(P), give rise to weakly active L-Ala-L-Phe(P) and L-Ala-L-Ser(P). Replacement of L-Ala in 1 by common and are amino acids can give rise to more potent in vitro antibacterials such as L-Nva-L-Ala(P). Synthetic variation of these more potent dipeptides leads to decreased activity. Phosphonooligopeptides such as (L-Ala)2-L-Ala(P) have a broader in vitro antibacterial spectrum than their phosphonodipeptide precursor, but this is not expressed in vivo, presumably due to rapid metabolism to 1. Stabilized compounds such as Sar-L-Nva-L-Nva-L-Ala(P) have been developed that are more potent in vivo and have a broader in vivo antibacterial spectrum than the parent phosphonodipeptide.
